$BFRI
Biofrontera Inc. Stock $bfri

$bfri Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224019878 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$7.839M	$7.912M	$8.733M
YoY Change	34.05%	-9.4%	-10.44%
Cost Of Revenue	$4.342M	$4.116M	$4.598M
YoY Change	50.35%	-10.48%	-10.72%
Gross Profit	$3.497M	$3.796M	$4.135M
YoY Change	18.14%	-8.2%	-10.13%
Gross Profit Margin	44.61%	47.98%	47.35%
Selling, General & Admin	$7.947M	$9.250M	$9.800M
YoY Change	-30.63%	-5.61%	27.09%
% of Gross Profit	227.25%	243.68%	237.0%
Research & Development	$621.0K	$17.00K
YoY Change	5545.45%
% of Gross Profit	17.76%	0.45%
Depreciation & Amortization	$130.0K	$21.00K	$22.00K
YoY Change	3.17%	-4.55%	-83.21%
% of Gross Profit	3.72%	0.55%	0.53%
Operating Expenses	$12.91M	$13.38M	$14.23M
YoY Change	-11.25%	-5.95%	84.48%
Operating Profit	-$5.071M	-$5.467M	-$5.500M
YoY Change	-41.71%	-0.6%	76.85%
Interest Expense	$620.0K	$1.421M	$2.000K
YoY Change	684.81%	70950.0%	-106.06%
% of Operating Profit
Other Income/Expense, Net	$4.834M	-$4.969M	-$1.981M
YoY Change	-530.07%	150.83%	-122.68%
Pretax Income	-$237.0K	-$10.44M	-$7.473M
YoY Change	-97.59%	39.65%	-233.66%
Income Tax	$20.00K	$1.000K	$5.000K
% Of Pretax Income
Net Earnings	-$257.0K	-$10.44M	-$7.478M
YoY Change	-97.39%	39.57%	-234.47%
Net Earnings / Revenue	-3.28%	-131.91%	-85.63%
Basic Earnings Per Share	-$0.05	-$2.88	-$0.28
Diluted Earnings Per Share	-$0.05	-$2.88	-$0.28
COMMON SHARES
Basic Shares Outstanding	5.089M shares	5.089M shares	26.70M shares
Diluted Shares Outstanding	5.091M shares	3.624M shares	26.70M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.389M	$3.840M	$21.10M
YoY Change	-57.75%	-81.8%	-6.45%
Cash & Equivalents	$4.379M	$3.817M	$13.51M
Short-Term Investments	$10.00K	$23.00K	$7.596M
Other Short-Term Assets	$5.632M	$5.719M	$1.586M
YoY Change	506.24%	260.59%	27.39%
Inventory	$3.946M	$6.905M	$6.670M
Prepaid Expenses
Receivables	$3.504M	$3.691M	$7.866M
Other Receivables	$0.00	$0.00	$3.750M
Total Short-Term Assets	$17.47M	$20.16M	$37.22M
YoY Change	-45.9%	-45.85%	-12.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$101.0K	$120.0K	$197.0K
YoY Change	-42.29%	-39.09%	-19.59%
Goodwill
YoY Change
Intangibles	$2.448M	$2.556M	$2.927M
YoY Change	-13.28%	-12.68%
Long-Term Investments
YoY Change
Other Assets	$324.0K	$328.0K	$384.0K
YoY Change	-35.71%	-14.58%	43.28%
Total Long-Term Assets	$4.103M	$4.420M	$4.742M
YoY Change	-10.98%	-6.79%	-28.92%
TOTAL ASSETS
Total Short-Term Assets	$17.47M	$20.16M	$37.22M
Total Long-Term Assets	$4.103M	$4.420M	$4.742M
Total Assets	$21.57M	$24.58M	$41.97M
YoY Change	-41.54%	-41.44%	-14.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.678M	$6.761M	$887.0K
YoY Change	276.35%	662.23%	55.34%
Accrued Expenses	$3.593M	$4.230M	$11.14M
YoY Change	-66.53%	-62.01%	42.41%
Deferred Revenue
YoY Change
Short-Term Debt	$296.0K	$2.355M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.268M	$14.04M	$20.45M
YoY Change	-63.44%	-31.36%	65.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$31.00K	$33.00K	$24.00K
YoY Change	-22.5%	37.5%	-99.88%
Total Long-Term Liabilities	$31.00K	$33.00K	$24.00K
YoY Change	-22.5%	37.5%	-99.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.268M	$14.04M	$20.45M
Total Long-Term Liabilities	$31.00K	$33.00K	$24.00K
Total Liabilities	$10.66M	$26.42M	$25.21M
YoY Change	-64.14%	4.79%	-20.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.3M	-$110.1M	-$87.00M
YoY Change	13.95%	26.55%
Common Stock	$5.000K	$5.000K	$27.00K
YoY Change	-81.48%	-81.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.91M	-$5.416M	$16.75M
YoY Change
Total Liabilities & Shareholders Equity	$21.57M	$24.58M	$41.97M
YoY Change	-41.54%	-41.44%	-14.71%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$257.0K	-$10.44M	-$7.478M
YoY Change	-97.39%	39.57%	-234.47%
Depreciation, Depletion And Amortization	$130.0K	$21.00K	$22.00K
YoY Change	3.17%	-4.55%	-83.21%
Cash From Operating Activities	-$4.720M	-$3.325M	-$3.700M
YoY Change	-54.33%	-10.14%	75.19%
INVESTING ACTIVITIES
Capital Expenditures	$2.000K	$57.00K	$14.00K
YoY Change		307.14%	-380.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$57.00K
YoY Change	-100.0%
Cash From Investing Activities	-$2.000K		-$14.00K
YoY Change	-101.12%		180.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.284M	$5.799M
YoY Change	377.76%
NET CHANGE
Cash From Operating Activities	-4.720M	-$3.325M	-$3.700M
Cash From Investing Activities	-2.000K		-$14.00K
Cash From Financing Activities	5.284M	$5.799M
Net Change In Cash	562.0K	$2.474M	-$3.703M
YoY Change	-106.21%	-166.81%	74.92%
FREE CASH FLOW
Cash From Operating Activities	-$4.720M	-$3.325M	-$3.700M
Capital Expenditures	$2.000K	$57.00K	$14.00K
Free Cash Flow	-$4.722M	-$3.382M	-$3.714M
YoY Change	-54.32%	-8.94%	76.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1		usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2024Q1	BFRI	Stock Issued During Period Value Exercise Of Prefunded Warrants StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants		usd
CY2024Q1	BFRI	Stock Issuance Of Series B Preferred Stock And Warrants Value StockIssuanceOfSeriesBPreferredStockAndWarrantsValue		usd
CY2024Q1	BFRI	Conversion Of Series B1 Preferred Into Common Stock Value ConversionOfSeriesB1PreferredIntoCommonStockValue		usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1		usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
CY2023Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2023Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3325000	usd
CY2023Q1	BFRI	Net Losses Recognized During Period On Equity Securities Sold NetLossesRecognizedDuringPeriodOnEquitySecuritiesSold		usd
CY2024Q1	BFRI	Accrued Legal Settlement Expenses Current AccruedLegalSettlementExpensesCurrent		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024Q1	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense		usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
CY2024Q1	BFRI	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree		usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	6905000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	10908000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	560000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	425000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	23075000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	134000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1612000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2629000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	482000	usd
CY2023Q4	us-gaap	Assets Assets	27932000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	690000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	691000	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4230000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4487000	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	2355000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	3904000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	14036000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18088000	usd
CY2024Q1	BFRI	Warrant Liabilities Non Current WarrantLiabilitiesNonCurrent	11731000	usd
CY2023Q4	BFRI	Warrant Liabilities Non Current WarrantLiabilitiesNonCurrent	4210000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	621000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	804000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	33000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	26421000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	23139000	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	19978828	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	19978828	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5089413	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5089413	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1517628	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1517628	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104666000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104441000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110087000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-99650000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-5416000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4793000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24575000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27932000	usd
CY2024Q1	BFRI	Products Revenues Net ProductsRevenuesNet	7901000	usd
CY2023Q1	BFRI	Products Revenues Net ProductsRevenuesNet	8715000	usd
CY2024Q1	BFRI	Revenues Related Party RevenuesRelatedParty	11000	usd
CY2023Q1	BFRI	Revenues Related Party RevenuesRelatedParty	18000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7912000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8733000	usd
CY2024Q1	BFRI	Selling General And Administrative Related Party SellingGeneralAndAdministrativeRelatedParty	-4000	usd
CY2023Q1	BFRI	Selling General And Administrative Related Party SellingGeneralAndAdministrativeRelatedParty	27000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-200000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	13379000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	14225000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5467000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5492000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3429000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1028000	usd
CY2024Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	3000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2941000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-316000	usd
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1407000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-35000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-10437000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7478000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.88
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.88
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.60
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.60
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3623593	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3623593	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1334950	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1334950	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4793000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	228000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-10437000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-5416000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23878000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23878000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	351000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7478000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	16751000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	16751000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-10437000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7478000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	21000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	22000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	179000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	139000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	107000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	105000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2941000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-200000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3429000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1028000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	228000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	351000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	66000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-316000	usd
CY2024Q1	BFRI	Noncash Interest Expense NoncashInterestExpense	151000	usd
CY2023Q1	BFRI	Noncash Interest Expense NoncashInterestExpense	89000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1576000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	381000	usd
CY2024Q1	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	165000	usd
CY2023Q1	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	-2720000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	119000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	830000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-4003000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-499000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-2250000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-792000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-166000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-134000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-261000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	274000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3325000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3689000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	57000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	57000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7662000	usd
CY2024Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1506000	usd
CY2024Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	357000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5799000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2474000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3703000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1543000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17408000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4017000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13705000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1173000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	22000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3700000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110100000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7300000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3800000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1300000	usd
CY2024Q1	BFRI	Discretionary Expenses DiscretionaryExpenses	5500000	usd
CY2023Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-20
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zqF82OPw0Ef7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_86B_zdbQkL3uQMI7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions by management that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities, as reported on the balance sheet date, and the reported amounts of revenues and expenses arising during the reporting period. The main areas in which assumptions, estimates and the exercising of judgment are appropriate relate to, valuation allowances for receivables and inventory, valuation of contingent consideration and warrant liabilities, realization of intangible and other long-lived assets, product sales allowances and reserves, share-based payments and income taxes including deferred tax assets and liabilities. Estimates are based on historical experience and other assumptions that are considered appropriate in the circumstances. They are continuously reviewed but may vary from the actual values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant	11731000	usd
CY2023Q4	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant	4210000	usd
CY2024Q1	BFRI	Stock Issued During Period Shares Investment In Equity Securities StockIssuedDuringPeriodSharesInvestmentInEquitySecurities	63415	shares
CY2023Q4	BFRI	Stock Issued During Period Shares Investment In Equity Securities StockIssuedDuringPeriodSharesInvestmentInEquitySecurities	177465	shares
CY2022Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	82000	usd
CY2023Q1	BFRI	Revenue From Contract With Customer Allowances And Reserves Provision Related To Current Period RevenueFromContractWithCustomerAllowancesAndReservesProvisionRelatedToCurrentPeriod	99000	usd
CY2023Q1	BFRI	Revenue From Contract With Customer Allowances And Reserves Credit Payments Made During Period RevenueFromContractWithCustomerAllowancesAndReservesCreditPaymentsMadeDuringPeriod	112000	usd
CY2023Q1	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	69000	usd
CY2023Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	112000	usd
CY2023Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	112000	usd
CY2024Q1	BFRI	Revenue From Contract With Customer Allowances And Reserves Provision Related To Current Period RevenueFromContractWithCustomerAllowancesAndReservesProvisionRelatedToCurrentPeriod	53000	usd
CY2024Q1	BFRI	Revenue From Contract With Customer Allowances And Reserves Credit Payments Made During Period RevenueFromContractWithCustomerAllowancesAndReservesCreditPaymentsMadeDuringPeriod	25000	usd
CY2024Q1	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	140000	usd
CY2024Q1	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	140000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	100000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2941000	usd
CY2024Q1	BFRI	Net Losses Recognized During Period On Equity Securities Sold NetLossesRecognizedDuringPeriodOnEquitySecuritiesSold	-98000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	101000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-2941000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	300000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	200000	usd
CY2024Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	49000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	15000	usd
CY2024Q1	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2023Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2093000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1986000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2556000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2629000	usd
CY2024Q1	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2024Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3700000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3817000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1343000	usd
CY2024Q1	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	200000	usd
CY2023Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	200000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4017000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1543000	usd
CY2023Q4	BFRI	Accrued Legal Settlement Expenses Current AccruedLegalSettlementExpensesCurrent	403000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2968000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2185000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	530000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1064000	usd
CY2024Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	97000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	118000	usd
CY2024Q1	BFRI	Accrued Product Revenue Allowances And Reserves AccruedProductRevenueAllowancesAndReserves	176000	usd
CY2023Q4	BFRI	Accrued Product Revenue Allowances And Reserves AccruedProductRevenueAllowancesAndReserves	149000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	459000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	568000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4230000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4487000	usd
CY2023Q4	BFRI	Legal Settlements Receivable Percentage LegalSettlementsReceivablePercentage	0.50	pure
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5089413	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	99486	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	39.36
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	10076	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.56
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	89410	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	42.83
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	30302	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	63.37
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	700000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M4D
CY2024Q1	us-gaap	Interest Expense InterestExpense	1421000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2000	usd
CY2023Q1	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense	89000	usd
CY2024Q1	BFRI	Interest Income InterestIncome	14000	usd
CY2023Q1	BFRI	Interest Income InterestIncome	56000	usd
CY2024Q1	BFRI	Interest Expense Net InterestExpenseNet	1407000	usd
CY2023Q1	BFRI	Interest Expense Net InterestExpenseNet	35000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-10437000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7478000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3623593	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3623593	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1334950	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1334950	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.88
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.88
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.60
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.60
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6793892	shares
CY2024Q1	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	option to extend the term of the lease for one five (5)-year period
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	573000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	582000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	238000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	31000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1424000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	113000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1311000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	690000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	621000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1311000	usd

Files In Submission

Name	View Source	Status
0001493152-24-019878-index-headers.html	Edgar Link	pending
0001493152-24-019878-index.html	Edgar Link	pending
0001493152-24-019878.txt	Edgar Link	pending
0001493152-24-019878-xbrl.zip	Edgar Link	pending
bfri-20240331.xsd	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex10-2.htm	Edgar Link	pending
ex10-2_001.jpg	Edgar Link	pending
ex10-3.htm	Edgar Link	pending
ex10-3_001.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
bfri-20240331_def.xml	Edgar Link	unprocessable
bfri-20240331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bfri-20240331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bfri-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BFRI
Biofrontera Inc. Stock $bfri

2024 Q2 Form 10-Q Financial Statement

#000149315224019878 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFRI Biofrontera Inc. Stock $bfri

2024 Q2 Form 10-Q Financial Statement

#000149315224019878 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFRI
Biofrontera Inc. Stock $bfri